The European Union Commission has approved Pfizer's ABRYSVO™ to protect infants and the elderly from Respiratory Syncytial Virus infections via maternal vaccination.

RLYB116, a potential long-acting solution, is a subcutaneously administered C5 inhibitor which is currently being developed for managing patients with complement-mediated diseases.

Bayer’s Kerendia (finerenone)  had gained approval for usage in managing chronic kidney diseases affiliated with type 2 diabetes two summers ago.

Stallerges Greer has disclosed a contract with Nestle regarding the use of Palforzia ® A global agreement to treat peanut allergies.

Exelixis Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors.

Comanche Biopharma grants Fast Track Status by FDA for CBP-4888, aimed at treating sFlt-1 induced early-onset preeclampsia

Abata Therapeutics reveals the second development candidate, ABA-201, designed for the management of Type 1 Diabetes

AusperBio Therapeutics, Inc.have declared today that the FDA has sanctioned the IND application for testing of AHB-137 in clinics.

Data analysis from a sample of 822 patients reveals noticeable mepolizumab in symptomatology among Mepolizumab-treated adult asthma sufferers a year post-treatment, regardless of the existence of concomitant medical conditions.

Carisma Therapeutics's primary candidate product, CT-0508, is set to be displayed at this year's 8th annual CAR-TCR conference.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has initiated dosing of the first patients in its ongoing REVERTIPF trial.

Genentech announced today that the Phase III ALINA study assessing Alecensa® (alectinib) has achieved its primary endpoint of disease-free survival (DFS) during a pre-determined interim analysis.